EP0213776A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of a cartilage-inducing factor (CIF) for the manufacture of a medicament for treating inflammation
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1986-08-04
•
Granted: —
•
Expires: 2006-08-04
Abstract
Abstract Inflammation, acute and/or chronic, is treated with a CIF (TGF-β). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration of activator or cofactor for efficacy.
Inventors
- 👤 Hanne Bentz
- 👤 Larry Ellingsworth
- 👤 Rosa Armstrong
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 13:27
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61P; A61P29/00; A61P37/00; A61P7/00; C07K14/51; C07K16/00; C07K16/18; C07K16/22; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
15 words
Use of a cartilage-inducing factor (CIF) for the manufacture of a medicament for treatment inflammation.
Claim 2
Dependent Claim
15 words
Use of a cartilage-inducing factor (CIF) for the manufacture of a medicament for treatment inflammation.
Claim 3
Dependent Claim
20 words
Use of a CIF for the manufacture of a medicament for treating a dysfunction or malfunction of hematopoiesis or lymphopoiesis.
Claim 4
Dependent Claim
20 words
Use of a CIF for the manufacture of a medicament for treating a dysfunction or malfunction of hematopoiesis or lymphopoiesis.
Claim 5
Dependent Claim
38 words
Use of CIF as in claims l or 2, wherein the CIF is a homodimer whose chains each have (a) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Ser-Ser-Thr-Glu-Lys-Asn-Cys-Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-; or (b) the following partial N-terminal amino acid sequence: Ala-Leu-Asp-Ala-Ala-Tyr-Cys-Phe-Arg-Asn-Val-Glu-Asp-Asn-Cys-Cys-Leu-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Lys-Arg-Asp-Leu-Gly-Trp.
Claim 6
Dependent Claim
28 words
Use of a CIF as in claims l or 2, wherein the CIF is a homodimer whose chains each have the amino acid sequence shown in Figure l.
Claim 7
Dependent Claim
21 words
Use of a CIF as in claim l or 2, wherein the CIF is substantially free of activating agent or co-factor.
Claim 8
Dependent Claim
18 words
use of a CIF as in any one of the preceding claims, wherein the CIF is applied systemically.
Claim 9
Dependent Claim
17 words
Use of a CIF as in any one of claims l-5, wherein the CIF is applied locally.
Claim 10
Dependent Claim
23 words
Use of a CIF as in Claim 7, wherein the CIF is applied as an implant in combination with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
15 words
Use of a CIF as in claim 8, wherein the carrier is a collagenous carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.